AUA Partners with Federal Agencies to Standardize Postmenopausal Care — American Urological Association, Inc.

Event summary

AUA and UCF formalize partnership with HHS, FDA, and CDC to address genitourinary syndrome of menopause (GSM) and recurrent UTIs in postmenopausal women.
HHS and CDC issue joint policy statement affirming the safety and efficacy of vaginal estrogen therapy for postmenopausal care.
AUA released its GSM guideline in 2025, developed in collaboration with SUFU and AUGS, providing evidence-based recommendations for clinicians.
Partnership aims to expand clinician education, develop patient-facing materials, and promote preventive strategies to reduce antibiotic use.

The big picture

The partnership addresses a growing public health burden of recurrent UTIs in postmenopausal women, contributing to antimicrobial resistance and rising healthcare costs. By aligning federal agencies with medical societies, the initiative aims to standardize care and improve patient outcomes on a national scale. The collaboration underscores the need for coordinated efforts to tackle menopause-related health challenges, reflecting broader trends in healthcare governance and preventive medicine.

What we're watching

Regulatory Alignment: How the joint policy statement will influence clinical practice and insurance coverage for vaginal estrogen therapy.
Educational Impact: The pace at which clinician and patient education materials are adopted and their effect on treatment adherence.
Antibiotic Resistance: Whether preventive strategies reduce unnecessary antibiotic use and lower healthcare costs.